Kaiyo Genomics Inc.

Kaiyo Genomics specializes in marine biodiversity genomics, developing novel drug candidates from deep-sea organisms. Their lead compound KG-401 targets treatment-resistant cancers using compounds derived from deep-sea sponges.

• Pre-revenue biotech with significant cash burn
• Clinical trial failure risk for lead compound
• Regulatory approval timeline uncertainty in both Japan and US markets